ArticleAntimicrobial agents and chemotherapy2018
Novel Self-Assembled Micelles Based on Cholesterol-Modified Antimicrobial Peptide (DP7) for Safe and Effective Systemic Administration in Animal Models of Bacterial Infection.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Topical strategies for antimicrobial delivery of peptide medicines for the management of chronic wounds.Discover nano · 2026Review
- KK2DP7 Stimulates CD11bAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Polymer Micelles as Nanocarriers of Bioactive Peptides.Polymers · 2025Review
- Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.Signal transduction and targeted therapy · 2025Review
- A Novel Systemic siDR6 Delivery System Based on DP7-C for the Treatment of Metastatic Lung Cancer.International journal of nanomedicine · 2025Article
- Peptide-Based Biomaterials for Combatting Infections and Improving Drug Delivery.Pharmaceutics · 2024Review
- Antimicrobial Peptide Delivery Systems as Promising Tools Against Resistant Bacterial Infections.Antibiotics (Basel, Switzerland) · 2024Review
- The utilization of nanotechnology in the female reproductive system and related disorders.Heliyon · 2024Review
- Advanced delivery systems for peptide antibiotics.Advanced drug delivery reviews · 2023Review
- Efficient Synergistic Antibacterial Activity of α-MSH Using Chitosan-Based Versatile Nanoconjugates.ACS omega · 2023Article
- Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment.Archives of pharmacal research · 2022Review
- Nanocarriers for effective delivery: modulation of innate immunity for the management of infections and the associated complications.Journal of nanobiotechnology · 2022Review
- Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.Biological reviews of the Cambridge Philosophical Society · 2022Review
- Engineering neoantigen vaccines to improve cancer personalized immunotherapy.International journal of biological sciences · 2022Review
- Current Advances in Lipid and Polymeric Antimicrobial Peptide Delivery Systems and Coatings for the Prevention and Treatment of Bacterial Infections.Pharmaceutics · 2021Review
- Micellar Drug Delivery Systems Based on Natural Biopolymers.Polymers · 2021Review
- Analogs of the Cathelicidin-Derived Antimicrobial Peptide PMAP-23 Exhibit Improved Stability and Antibacterial Activity.Probiotics and antimicrobial proteins · 2021Article
- The Potential of Modified and Multimeric Antimicrobial Peptide Materials as Superbug Killers.Frontiers in chemistry · 2021Review
- Enhancing the antibacterial activity of antimicrobial peptide PMAP-37(F34-R) by cholesterol modification.BMC veterinary research · 2020Article
- The Efficacy of Cholesterol-Based Carriers in Drug Delivery.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing to their broad-spectrum antibacterial properties, multitarget effects, and low drug resistance, antimicrobial peptides (AMPs) have played critical roles in the clinical therapy of drug-resistant bacterial infections. However, the potential hazard of hemolysis following systemic administration has greatly limited their application. Here, we developed a novel AMP derivative, DP7-C, by modifying a formerly identified highly active AMP (DP7) with cholesterol to form an amphiphilic conjugate. The prepared DP7-C easily self-assembled into stable nanomicelles in aqueous solution. The DP7-C micelles showed lower hemolytic activity than their unconjugated counterparts toward human red blood cells and a maximum tolerated dose of 80 mg/kg of body weight in mice via intravenous injection, thus demonstrating improved safety. Moreover, by eliciting specific immunomodulatory activities in immune cells, the DP7-C micelles exerted distinct therapeutic effects in zebrafish and mouse models of infection. In conclusion, DP7-C micelles may be an excellent candidate for the treatment of bacterial infections in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.